[Aβ immunotherapy for Alzheimer's disease].

Area of Science:

• Neuroscience
• Immunology
• Pathology

Context:

• Alzheimer's disease (AD) is a neurodegenerative disorder marked by amyloid-beta (Aβ) plaques and tau tangles.
• The amyloid-cascade hypothesis posits Aβ as a key driver of AD pathogenesis.
• Current understanding of AD pathomechanisms requires further elucidation.

Purpose:

• To review the development and outcomes of Aβ immunization therapies for Alzheimer's disease.
• To analyze the efficacy and safety challenges associated with Aβ immunotherapy.
• To explore the neuropathological findings and potential mechanisms behind adverse effects.

Summary:

• Aβ immunization strategies, including active and passive approaches, aim to clear Aβ plaques and prevent neuronal damage.
• Clinical trials (e.g., AN1792, bapineuzumab, solanezumab) have shown limited clinical benefits and revealed side effects such as ARIA (amyloid-related imaging abnormalities).
• Neuropathological studies indicate Aβ clearance and reduced phosphorylated-tau, but also cerebral amyloid angiopathy deterioration and increased microhemorrhages, possibly linked to impaired lymphatic drainage.

Impact:

• Aβ immunization holds therapeutic potential for AD, but overcoming side effects like ARIA is crucial for clinical application.
• Understanding the role of cerebral amyloid angiopathy and lymphatic drainage in immunotherapy-induced adverse events is essential.
• Further research is needed to refine Aβ immunotherapy for safe and effective AD treatment.